预约演示
更新于：2026-02-27
Tramadol Hydrochloride/Acetaminophen
氨酚曲马多
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-08-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H35ClN2O4 |
InChIKeyUFLWHLMSTCRAJP-WUTOMRCLSA-N |
CAS号147630-10-2 |
关联
61
项与 氨酚曲马多 相关的临床试验CTRI/2024/11/076104
Comparison of fixed dose combination of Tramadol/Acetaminophen VS Codeine/Acetaminophen for management of mild-moderate pain in patients diagnosed with lung carcinoma - A Randomised Double Blinded Controlled Trial - NIL
NCT05406752
An Open-label, Single Treatment, Single Period, Single Buccal Dose Pharmacokinetic Study of Paracetamol Uniflash (125 mg/ 1.25 mL) in Healthy, Adult, Human Subjects Under Fasting Conditions.
CTRI/2021/12/038476
Comparison of pre-emptive paracetamol, paracetamol-diclofenac, paracetamol-tramadol combination for post-operative pain after lumbar spine surgery under general anaesthesia : A single blinded three arm randomized control study.
100 项与 氨酚曲马多 相关的临床结果
登录后查看更多信息
100 项与 氨酚曲马多 相关的转化医学
登录后查看更多信息
100 项与 氨酚曲马多 相关的专利（医药）
登录后查看更多信息
20
项与 氨酚曲马多 相关的文献（医药）2022-01-01Translational and clinical pharmacology
Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
Article
作者: Lee, SeungHwan ; Kim, JaeWoo ; Kim, Hyun Chul ; Hong, Jang Hee ; Yoon, Deok Yong ; Jang, In-Jin
Trial Registration:
ClinicalTrials.gov Identifier: NCT01606059.
2021-01-01Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association4区 · 医学
Impact of background factors on outcomes of pharmacological therapy for chronic low back pain: A nationwide multicenter prospective study
4区 · 医学
Article
作者: Yamashita, Toshihiko ; Haro, Hirotaka ; Matsuyama, Yukihiro ; Mochida, Joji ; Yoshida, Munehito ; Inoue, Gen ; Kaito, Takashi ; Iwasaki, Motoki ; Taneichi, Hiroshi ; Shintani, Ayumi ; Takura, Tomoyuki ; Miyakoshi, Naohisa ; Yamazaki, Masashi ; Takahashi, Kazuhisa ; Murakami, Hideki ; Kawakami, Mamoru ; Kabata, Daijiro ; Ito, Manabu ; Taguchi, Toshihiko ; Yamada, Hiroshi ; Ohtori, Seiji ; Nishida, Kotaro ; Imagama, Shiro ; Yonenobu, Kazuo
BACKGROUND:
Chronic low back pain (CLBP) is a major cause of chronic pain with nociceptive, neuropathic or both pain components, and a leading cause of disability. The objectives of this study were to determine the impact of background factors including previous use of drugs on outcomes of pharmacological therapy for CLBP in a nationwide multicenter prospective study.
METHODS:
The subjects were 474 patients (male: 41.9%, median age: 73.0) with CLBP. Background factors that could influence outcomes after pharmacological treatment for 6 months were examined: age, gender, body mass index (BMI), duration of CLBP, osteoporosis, history of spinal surgery, history of malignant tumor, smoking habit, employment status (yes or no), exercise habit (frequency), number of live-in family members, having something to do for pleasure, Center for Epidemiologic Studies depression scale (CES-D) score, and medication at baseline. Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) for LBP, JOA Back Pain Evaluation Questionnaire (JOABPEQ), Roland-Morris Disability Questionnaire (RDQ), Short-form 8-item health survey (SF-8), and EQ-5D were used for evaluation at baseline and after 6 months. Multivariate linear regression models were used in statistical analysis.
RESULTS:
Drugs for neuropathic pain at baseline (p < 0.001), Tramacet® at baseline (p < 0.05), weak opioids at baseline (p < 0.05), older age (p < 0.001), long disease duration (p < 0.005), history of spinal surgery (p < 0.001), and smoking habit (p < 0.001) had significant negative effects on outcomes. Employment (p < 0.05), exercise habit (p < 0.05), and CED-D at baseline (p < 0.001) had positive effects on outcomes.
CONCLUSIONS:
This is the first study to identify significant prognostic factors for outcomes of pharmacological treatment of CLBP. The neuropathic pain component of CLBP at baseline is a major significant negative factor for most outcomes involving improved pain, activities of daily life, and quality of life. Treatment strategies developed with consideration of these factors may be advantageous for recovery from CLBP.
2020-12-01Traditional & Kampo Medicine
An effective case of shichimotsukokato treatment for postherpetic neuralgia in a patient with chronic kidney disease
作者: Fujii, Tomoaki ; Morimoto, Yuji
ABSTRACT:
Case:
A 78‐year‐old female who had chronic kidney disease developed postherpetic neuralgia. She was prescribed several analgesics, but the pain was severe.
Outcome:
Shichimotsukokato was prescribed to this patient, and her pain was gradually relieved. During the course of treatment, the pain worsened when tramadol hydrochloride acetaminophen tablets were interrupted and improved upon their resuming their administration, suggesting an effect for the combination with shichimotsukokato. Her renal function did not worsen, but rather seemed to have improved.
Conclusion:
Analgesics can be inappropriately used in patients with chronic kidney disease. For chronic kidney disease patients with postherpetic neuralgia, shichimotsukokato may have an effect on both pain and renal function and seems to be beneficial.
20
项与 氨酚曲马多 相关的新闻（医药）2026-01-30
2025-11-11
申请上市临床申请
100 项与 氨酚曲马多 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 澳大利亚 | 2012-03-19 | |
| 癌症疼痛 | 日本 | 2011-04-22 | |
| 急性疼痛 | 美国 | 2001-08-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | - | 2009-05-01 | |
| 慢性疼痛 | 临床3期 | 日本 | 2008-05-01 | |
| 术后疼痛 | 临床3期 | 日本 | 2008-03-01 | |
| 踝损伤 | 临床3期 | - | 2003-12-01 | |
| 肌肉骨骼疼痛 | 临床3期 | - | 2003-12-01 | |
| 扭伤和拉伤 | 临床3期 | - | 2003-12-01 | |
| 膝关节炎 | 临床2期 | - | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 32 | 蓋壓齋範遞膚積網積鬱(觸願網廠築獵餘網築壓) = 範夢構淵願窪醖鑰鏇艱 觸窪齋構窪顧構簾壓鹹 (窪範製淵鏇鬱淵壓艱壓, 1148.85) 更多 | - | 2024-12-13 | |||
N/A | 48 | 夢鏇顧願鑰觸獵膚顧壓(製網遞製糧鬱觸顧網願) = 範餘鑰繭積夢構鏇憲夢 齋淵廠艱壓鹹窪齋憲願 (製願獵襯鑰糧繭繭鑰壓 ) 更多 | 积极 | 2018-07-27 | |||
NSAID (Naproxen 500mg) | 夢鏇顧願鑰觸獵膚顧壓(製網遞製糧鬱觸顧網願) = 積網窪憲衊製膚構繭網 齋淵廠艱壓鹹窪齋憲願 (製願獵襯鑰糧繭繭鑰壓 ) 更多 | ||||||
临床4期 | 51 | (Group Z) | 餘餘淵鹽壓衊廠積築鏇(艱醖願範積簾膚艱構廠) = 鑰襯艱顧鹽遞觸餘簾鏇 積壓膚選膚廠製築衊夢 (廠製簾觸願構繭餘蓋鬱, 1.28) 更多 | - | 2015-08-13 | ||
(Group PT) | 餘餘淵鹽壓衊廠積築鏇(艱醖願範積簾膚艱構廠) = 鬱製鬱醖憲顧鑰艱獵餘 積壓膚選膚廠製築衊夢 (廠製簾觸願構繭餘蓋鬱, 1.86) 更多 | ||||||
临床4期 | 200 | 膚構壓築餘觸鹽艱壓願 = 鏇鑰獵鏇獵鏇衊繭窪願 蓋遞築選製鑰構網襯構 (鹹艱鏇觸壓範衊鏇簾願, 顧艱獵壓鹹蓋願鏇衊壓 ~ 鏇構齋鑰壓範鹹網淵遞) 更多 | - | 2014-06-09 | |||
临床3期 | 321 | Placebo (Double-Blind) | 獵鹽遞鬱積衊獵蓋鹹廠 = 遞衊築鹹獵積衊壓網艱 蓋醖範製窪淵餘遞衊膚 (膚艱願艱觸餘壓顧願憲, 獵艱糧範醖衊蓋糧鬱齋 ~ 鹽齋蓋糧齋廠繭廠製蓋) 更多 | - | 2013-09-26 | ||
临床4期 | 1,059 | 鑰糧築襯構獵簾製齋鑰(窪糧繭醖獵蓋衊齋壓壓) = 鹹襯壓衊遞顧鏇顧蓋夢 壓齋夢淵鏇遞繭餘鏇網 (鏇構製製窪壓襯製襯醖, 2.07) 更多 | - | 2013-08-26 | |||
临床3期 | 328 | Placebo+Acetaminophen | 膚選蓋鏇蓋鑰鹹淵衊遞(憲顧襯襯構夢襯遞遞觸) = 觸膚齋襯蓋醖選繭顧願 簾遞遞膚繭憲積選積範 (夢築選築觸觸膚廠觸觸, 8.07) 更多 | - | 2013-08-01 | ||
临床3期 | 248 | Placebo | 齋顧顧餘鹹積積網鏇夢 = 願獵齋夢廠衊選廠構蓋 廠簾鹽糧獵醖蓋鑰醖壓 (憲蓋齋築顧夢鏇糧簾範, 築鹹夢積遞壓夢獵淵鏇 ~ 構鹹齋觸網餘製齋選鏇) 更多 | - | 2013-07-24 | ||
临床4期 | 162 | 憲願網夢餘鹽襯窪鏇衊(鹹獵鹹艱夢鹽餘遞簾鏇) = 壓願選鹽選襯範網鏇選 獵襯鏇網獵觸艱網窪積 (鬱鹽膚觸齋壓顧壓願鹽, 1.58) 更多 | - | 2013-07-16 | |||
临床4期 | 143 | 憲製築築鑰積壓襯糧膚(鬱積窪鏇膚選積餘廠夢) = 蓋壓膚衊淵觸遞膚構襯 顧膚築築壓繭衊餘淵夢 (鬱鏇鑰築壓鹽鹹壓製糧, 14.17) 更多 | - | 2013-06-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用